Principal component analysis for automated classification of 2D spectra and interferograms of protein therapeutics: influence of noise, reconstruction details, and data preparation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of biomolecular NMR"
DOI: 10.1007/s10858-020-00332-y
Abstract: Protein therapeutics have numerous critical quality attributes (CQA) that must be evaluated to ensure safety and efficacy, including the requirement to adopt and retain the correct three-dimensional fold without forming unintended aggregates. Therefore, the ability… read more here.
Keywords: component analysis; protein therapeutics; principal component; analysis ... See more keywords
Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.
Sign Up to like & getrecommendations! Published in 2020 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2020.120461
Abstract: The parenteral administration of protein therapeutics is increasingly gaining importance for the treatment of human diseases. However, the presence of practically impermeable blood-brain barriers greatly restricts access of such pharmaceutics to the brain. Treating brain… read more here.
Keywords: protein therapeutics; treating brain; brain diseases; brain barriers ... See more keywords
Polyelectrolyte complexes as prospective carriers for the oral delivery of protein therapeutics
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Pharmaceutics and Biopharmaceutics"
DOI: 10.1016/j.ejpb.2016.11.005
Abstract: Graphical abstract Figure. No Caption available. ABSTRACT The oral administration of protein therapeutics is hindered by the multitude of barriers confronted by these molecules along the gastrointestinal tract (i.e., acidic environment, proteolytic degradation, mucosal barrier,… read more here.
Keywords: protein; polyelectrolyte complexes; protein therapeutics; delivery ... See more keywords
A Rapid High-Sensitivity Reversed -Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2019.04.029
Abstract: Polysorbate 20 (PS20), a widely used surfactant in protein therapeutics, has been reported to undergo hydrolytic degradation during product storage, causing the release of free fatty acids. The accumulation of free fatty acids in protein… read more here.
Keywords: degradation; protein therapeutics; high sensitivity; method ... See more keywords
Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations
Sign Up to like & getrecommendations! Published in 2018 at "Regulatory Toxicology and Pharmacology"
DOI: 10.1016/j.yrtph.2018.10.003
Abstract: ABSTRACT Protein therapeutics represent a rapidly growing proportion of new medicines being developed by the pharmaceutical industry. As with any new drug, an Occupational Exposure Limit (OEL) should be developed to ensure worker safety. Part… read more here.
Keywords: protein therapeutics; inhalation exposure; bioavailability; exposure ... See more keywords
Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.0c01218
Abstract: The current standard of care for antivascular endothelial growth factor (VEGF) treatment requires frequent intravitreal (IVT) injections of protein therapeutics, as a result of limited retention within the eye. A thorough understanding of the determinants… read more here.
Keywords: pharmacokinetics intravitreally; protein therapeutics; ocular pharmacokinetics; care ... See more keywords
Mechano-bioconjugation Strategy Empowering Fusion Protein Therapeutics with Aggregation Resistance, Prolonged Circulation, and Enhanced Antitumor Efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American Chemical Society"
DOI: 10.1021/jacs.2c06532
Abstract: Bioconjugation is a powerful protein modification strategy to improve protein properties. Herein, we report mechano-bioconjugation as a novel approach to empower fusion protein therapeutics and demonstrate its utility by a protein heterocatenane (cat-IFN-ABD) containing interferon-α2b… read more here.
Keywords: fusion protein; bioconjugation; ifn abd; mechano bioconjugation ... See more keywords
Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system
Sign Up to like & getrecommendations! Published in 2022 at "Immunological Reviews"
DOI: 10.1111/imr.13164
Abstract: Over a century after the discovery of the complement system, the first complement therapeutic was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It was a long‐acting monoclonal antibody (aka 5G1‐1, 5G1.1, h5G1.1, and… read more here.
Keywords: complement; therapeutics lessons; complement cascade; complement system ... See more keywords
Developing protein therapeutics
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacy and Pharmacology"
DOI: 10.1111/jphp.12921
Abstract: Biologics are protein-based drug products (DP) used as therapeutics. To date, more than 60 biologics are commercially approved for use as therapeutics in various malignancies. More than 1300 other biologics candidates are in clinical development,… read more here.
Keywords: issue; protein therapeutics; drug; oncology ... See more keywords